Dyadic International, Inc (NASDAQ:DYAI) VP Ronen Tchelet Sells 10,000 Shares of Stock

Dyadic International, Inc (NASDAQ:DYAI) VP Ronen Tchelet sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $5.74, for a total transaction of $57,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ronen Tchelet also recently made the following trade(s):

  • On Wednesday, July 10th, Ronen Tchelet sold 10,000 shares of Dyadic International stock. The shares were sold at an average price of $5.87, for a total transaction of $58,700.00.
  • On Monday, June 17th, Ronen Tchelet sold 20,000 shares of Dyadic International stock. The shares were sold at an average price of $6.11, for a total transaction of $122,200.00.

NASDAQ:DYAI traded down $0.04 during trading hours on Thursday, hitting $6.05. The stock had a trading volume of 40,487 shares, compared to its average volume of 62,598. Dyadic International, Inc has a one year low of $1.40 and a one year high of $7.30.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, research analysts anticipate that Dyadic International, Inc will post -0.3 EPS for the current year.

A number of large investors have recently modified their holdings of the business. Bandera Partners LLC bought a new stake in shares of Dyadic International during the second quarter worth $9,534,000. Vanguard Group Inc. bought a new stake in shares of Dyadic International during the second quarter worth $4,443,000. Northeast Financial Consultants Inc bought a new stake in shares of Dyadic International during the second quarter worth $1,565,000. Bank of America Corp DE bought a new stake in shares of Dyadic International during the second quarter worth $577,000. Finally, Pekin Hardy Strauss Inc. bought a new stake in shares of Dyadic International during the second quarter worth $384,000. 0.40% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have commented on DYAI. TheStreet raised shares of Dyadic International from a “d” rating to a “c” rating in a research note on Wednesday, April 17th. Noble Financial reaffirmed a “buy” rating and issued a $9.00 target price on shares of Dyadic International in a research note on Monday, July 8th. Finally, ValuEngine downgraded shares of Dyadic International from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

Further Reading: Why is the price target of stocks important?

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.